Treatment and Clinical Outcomes Among SLE Patients in Pregnancy
Treatment and Clinical Outcomes Among SLE Patients in Pregnancy: A Real World Study
Qilu Hospital of Shandong University
200 participants
Jan 1, 2018
INTERVENTIONAL
Conditions
Summary
Systemic lupus erythematosus (SLE) is a kind of systemic autoimmune disease which can cause multiple organs and system damage, which often occurs in women of childbearing age. Compared with healthy pregnant women, SLE patients have higher incidence of premature delivery, preeclampsia and fetal loss during pregnancy. Since SLE patients usually have disease activity during pregnancy and postpartum, and a variety of maternal and fetal diseases are closely related to SLE, it is very important to monitor the disease activity and drug treatment of SLE patients during pregnancy.
Eligibility
Inclusion Criteria3
- Patients diagnosed with systemic lupus erythematosus (SLE) (ACR criteria, 1997);
- Pregnant women aged 20-45 years old;
- Willing to participate in this study, willing to medication and follow-up according to the treatment plan, and sign the informed consent.
Exclusion Criteria14
- The cause of previous abortion was known:
- Known chromosomal abnormalities in the parent, maternal or embryo.
- \- Page 3 of 4 \[DRAFT\] -• Endocrine dysfunction of pregnant women: luteal dysfunction; Polycystic ovarian syndrome; Ovarian premature failure (FSH
- ≥ 20uu/ L) in follicular stage;
- Hyperprolactinemia thyroid disease; Other hypothalamic pituitary adrenal axis abnormalities in diabetes mellitus.
- Abnormal anatomy of pregnant women: abnormal uterus; Asherman syndrome; The uterine fibrosis of cervical insufficiency is more than 5 cm. Vaginal infection.
- Any known serious heart disease, liver, kidney, blood or endocrine disease.
- Any active infection Active viral hepatitis includes hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV). Active infections include small intestine herpes zoster virus (VZV), human immunodeficiency virus (HIV), syphilis or tuberculosis.
- Allergic to prednisone, hydroxychloroquine, low molecular weight heparin or aspirin.
- The history of the disease is as follows:
- There was a history of peptic ulcer or upper gastrointestinal bleeding in the past.
- The past history of malignant tumor.
- The past history of epilepsy or psychosis.
- Women who disagree or cannot complete the follow-up during pregnancy and after delivery.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Drug: 1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred 2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response. Other Names: HCQ 3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy. Other Names: Asp 4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response. Other Names: LMWH
Drug: 1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred 2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response. Other Names: HCQ
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04976465